Evidence map›Paper›PMID 38628784›Full record

ArticleACS medicinal chemistry letters2024

Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable

Mayako Michino, Tanweer A Khan, Michael W Miller, Yoshiyuki Fukase, Jeremie Vendome, Carolina Adura, J Fraser Glickman, Yiman Liu, Liling Wan, C David Allis and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Discovery of a Highly Potent and Selective ENL Degrader.Journal of medicinal chemistry · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Mayako MichinoSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-5469-025X
Tanweer A KhanSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
Michael W MillerSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
Yoshiyuki FukaseSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
Jeremie VendomeSchrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036, United States.
Carolina AduraFisher Drug Discovery Resource Center, The Rockefeller University, New York, New York 10065, United States.
J Fraser GlickmanFisher Drug Discovery Resource Center, The Rockefeller University, New York, New York 10065, United States.
Yiman LiuDepartment of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.
Liling WanDepartment of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.
C David AllisLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, United States.
Andrew W StamfordSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
Peter T MeinkeSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-7548-6215
Louis M RenzettiBridge Medicines, The Rockefeller University, 1230 York Avenue, Smith Hall Annex, C-Floor, New York, New York 10065, United States.
Stacia KargmanSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
Nigel J LivertonSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.
David J HugginsSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave, Box 122, New York, New York 10065, United States.ORCID https://orcid.org/0000-0003-1579-2496
Tri-Institutional Therapeutics Discovery Institute · USRockefeller University · USCancer Research Institute · USCornell University · USSchrodinger (United States) · US

Funding

Transcriptional control by the epigenetic reader ENL in human cancerR00CA226399 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WAN, LILING · 2020 to 2022
$747k
NCI NIH HHS R00 CA226399
6 · The paper itself

Abstract

Eleven-nineteen leukemia (ENL) is an epigenetic reader protein that drives oncogenic transcriptional programs in acute myeloid leukemia (AML). AML is one of the deadliest hematopoietic malignancies, with an overall 5-year survival rate of 27%. The epigenetic reader activity of ENL is mediated by its YEATS domain that binds to acetyl and crotonyl marks on histone tails and colocalizes with promoters of actively transcribed genes that are essential for leukemia. Prior to the discovery of

Identifiers

PMID38628784
PMCPMC11017412
OpenAlexW4392697197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.